LIVE TV
ZEE Business
ZEE BUSINESS
हिंदी में पढ़ें  हिंदी में पढ़ें
Live TV
Live TV
  • Home
  • Personal Finance
    • PPF
    • Mutual Funds
    • Income tax
    • EPFO
    • Income Tax Calculator
    • Personal Loan Calculator
    • Car Loan Calculator
    • Home Loan Calculator
    • SIP calculator
    • SWP Calculator
    • MF Returns Calculator
    • Lumpsum Calculator
  • India
    • Companies
    • Property
    • Startups
    • Uidai
  • Economy
    • Aviation
  • Tech
    • Mobiles
    • Apps
  • Auto
    • Cars
    • Bikes
  • Markets
    • Commodities
    • Currency
  • Jobs
  • Indian Railways
  • World
    • Economy
    • Politics
    • Markets
  • videos
  • photos
  • Authors
  • More ...
    • VIDEOS
    • PHOTOS
Read in App
Business News » Markets News

Laurus Labs share price: Sharekhan retains Buy recommendation with a revised price target of Rs 450

Sharekhan had an interaction with Laurus Labs management and their commentary was positive, pointing towards a robust growth outlook. Laurus’ formulations business is on a strong growth footing, backed by a higher quantum of launches in the US as well as opportunities from in-licensing of products, in addition to traction in anti-retrovirals (ARVs).

  • Twitter
  • Facebook
  • Linkedin
  • whatapp
  • View in App
Laurus Labs share price: Sharekhan retains Buy recommendation with a revised price target of Rs 450
Laurus Labs API segment is also well set to clock strong growth backed by the company’s increasing focus to diversify into new therapy areas - anti-diabetes and cardiology: Image taken from companies website
Reported By: ZeeBiz WebTeam
Written By: Rahul Kamdar
Edited By: Harish Dugh
Updated: Thu, Mar 11, 2021
09:30 am
Mumbai, ZeeBiz WebDesk
RELATED NEWS
Stocks to Buy with Anil Singhvi – Experts Kunal Saraogi, Rakesh Bansal pick Laurus Labs as their Special Pick for today Stocks to Buy with Anil Singhvi – Experts Kunal Saraogi, Rakesh Bansal pick Laurus Labs as their Special Pick for today
Laurus share price: Antique Stock Broking initiates coverage with a Buy rating and a target price of Rs 574 Laurus share price: Antique Stock Broking initiates coverage with a Buy rating and a target price of Rs 574
Laurus Labs share price: Anand Rathi maintains Buy rating with target price of Rs 424 per share Laurus Labs share price: Anand Rathi maintains Buy rating with target price of Rs 424 per share
Laurus Labs Share price target Rs 410: Robust growth outlook, says Sharekhan Laurus Labs Share price target Rs 410: Robust growth outlook, says Sharekhan
Laurus Labs Share Price: Company forays into Lucrative Biotech Space Laurus Labs Share Price: Company forays into Lucrative Biotech Space

Sharekhan had an interaction with Laurus Labs management and their commentary was positive, pointing towards a robust growth outlook. Laurus’ formulations business is on a strong growth footing, backed by a higher quantum of launches in the US as well as opportunities from in-licensing of products, in addition to traction in anti-retrovirals (ARVs). Sharekhan retains Buy recommendation on Laurus Labs with a revised price target of Rs 450. Laurus Labs share price closed yesterday at Rs 365, up Rs 18 or 5.3%.

Laurus Labs API segment is also well set to clock strong growth backed by the company’s increasing focus to diversify into new therapy areas - anti-diabetes and cardiology along with an eye to gain a foothold in the second line treatment for ARVs. Laurus Labs’ synthesis business is also expected to grow in double digits backed by client additions and increasing commercialization of products.

See Zee Business Live TV Streaming Below:

Laurus Labs has incorporated a dedicated subsidiary to house the synthesis business, which would facilitate improved focus on growth. To cater to rising demand, Laurus Labs is expanding capacities, in two stages - the first leg of debottlenecking is expected to be completed by April 2021 and would add up around 15% of the capacities, while the second leg of expansion would be done by December 2021. Post this company would almost double its formulations capacities.

Further, the recent foray in the biologics space through Laurus Bio augurs well and the benefits would accrue over the medium term. Considering a long term horizon of 3-5 years, Laurus has charted out its growth trajectory encompassing all segments and the management aspires to grow its revenues beyond $1bn in size.

A strong management bandwidth, investments towards upskilling manpower and building capabilities and capacities would enable it to achieve the goal. The above positives point to a strong growth trajectory for Laurus Labs going ahead. Sharekhan expects Laurus Labs to report sales and adjusted profit CAGR of 32% and 73%, respectively, over FY2020-FY2023.

Laurus Labs Key Risks:

Deferral in product approvals or any negative outcome of facility inspection by regulators can affect earnings prospects

 

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

TAGS:
Laurus Labs
RELATED NEWS
Stocks to Buy with Anil Singhvi – Experts Kunal Saraogi, Rakesh Bansal pick Laurus Labs as their Special Pick for today Stocks to Buy with Anil Singhvi – Experts Kunal Saraogi, Rakesh Bansal pick Laurus Labs as their Special Pick for today
Laurus share price: Antique Stock Broking initiates coverage with a Buy rating and a target price of Rs 574 Laurus share price: Antique Stock Broking initiates coverage with a Buy rating and a target price of Rs 574
Laurus Labs share price: Anand Rathi maintains Buy rating with target price of Rs 424 per share Laurus Labs share price: Anand Rathi maintains Buy rating with target price of Rs 424 per share
Laurus Labs Share price target Rs 410: Robust growth outlook, says Sharekhan Laurus Labs Share price target Rs 410: Robust growth outlook, says Sharekhan
Laurus Labs Share Price: Company forays into Lucrative Biotech Space Laurus Labs Share Price: Company forays into Lucrative Biotech Space

LATEST NEWS

Maharashtra lockdown e-pass: Here's how to apply for e-pass online and offline, check link, and other details now

Titagarh Wagons has an order book of Rs 4,500 crore: Umesh Chowdhary

CBSE Class 10 Board Exam 2021 Result: BIG NEWS! Students DON'T MISS this LATEST UPDATE - all details here

Are you a PM-Kisan Samman Nidhi Yojana beneficiary? Did you get your Rs 2000 installment?

Shravan Rathod of Nadeem-Shravan fame DIES due to Covid 19-related complications

7th Pay Commission: Central government employees' salary, allowance update—what will change from July

CBSE Board Exam 2021 Class 12: Students DON'T MISS this LATEST UPDATE on REVISED DATESHEET - check all details here

Anil Singhvi decodes fall in US markets on Thursday, reveals strategy for investors

CBSE students' alert: BIG change! Board releases new assessment and evaluation practices—check details here

Stocks to buy with Anil Singhvi: Here are Vikas Sethi’s top two picks for good returns - GIC Housing Finance and Hindustan Zinc

  • India News
  • World News
  • Companies News
  • Market News
  • Personal Finance News
  • Technology News
  • Automobile News
  • Small Business News
  • Income Tax Calculator
  • Live TV
  • Videos
  • Photos
  • Author
  • Rss Feed
  • Advertise with us
  • Privacy Policy
  • Legal Disclaimer

Latest Trending Updates

  • EPFO
  • Budget 2020
  • Income Tax Return
  • Auto Expo 2020
  • Home Loan
  • Business News

Trending Topics

  • Income Tax
  • income Tax Calculator
  • 7th Pay Commission
  • Reserve Bank of India
  • GST
  • Latest Business News

Follow us on

zeebiz
zeebiz

Partner Sites

  • Zee News
  • Hindi News
  • Marathi News
  • Bengali News
  • Tamil News
  • Malayalam News
  • Gujarati News
  • Telugu News
  • Kannada News
  • DNA
  • WION
Copyright © Zee Media Corporation Ltd. All rights reserved